Abstract:Background: The robustness and reproducibility of transcriptomics-derived models were limited by the various microenvironmental conditions like stromal context and tumor purity. We aimed to explore a robust prognostic and immunotherapeutic predictive model by differentiating cell origins in lung adenocarcinoma (LUAD).Methods: A total of 2,451 patients in 12 independent cohorts with transcriptomic data, including 10 public datasets and two in-house cohorts, were analyzed. The tumor immune cell score (TICS) and tumor stromal score (TSCS) was developed depending on the candidate immune or stromal cells in the training meta-cohorts (n=6), and then verified in four datasets. Therapeutic responses including immune checkpoint inhibitors (ICIs), chemotherapy and tyrosine kinase inhibitor (TKI) were compared between high- and low- TICS groups in the advanced-stage LUAD.Finding: The TICS, instead of TSCS, contributed majorly for predicting clinical outcomes in LUAD. The high TICS was associated with a prolonged overall survival (OS) in the training meta-cohorts (HR 0·55, 95%CI 0·45-0·66) and was validated in three public cohorts and one in-house cohort. The prognostic efficacy of TICS was more significant in the early-stage LUAD (HR=0·49, 95%CI: 0·38-0·63). For the advanced-stage LUAD, high TICS predicted a superior OS in patients who treated with ICIs (HR 0·09, 95% CI 0·02-0·32) instead of chemotherapy (HR 0·84, 95% CI 0·30-2·30) or TKI (HR 1·20, 95% CI 0·08-20·00).Interpretation: TICS is associated with survival in patients with LUAD, and may serve as a predictor for the benefit of ICIs in advanced LUAD.Funding Information: National Natural Sciences Foundation (82102886 for JX); Beijing Nova Program (Z211100002121055 for ZY); the Special Research Fund for Central Universities, Peking Union Medical College (3332021029 for JX); National Natural Sciences Foundation (82203827 for ZY); the Special Research Fund for Central Universities, Peking Union Medical College (3332021028 for ZY); Beijing Natural Science Foundation (7222146 for ZY); Guangdong Association of Clinical Trials (GACT) /Chinese Thoracic Oncology Group (CTONG) and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (Grant No. 2017B030314120); Beijing Hope Run Special Fund of Cancer Foundation of China (LC2021B22, LC2020B09, LC2020A33); the National Natural Sciences Foundation (81871889 and 82072586 for ZW) and Beijing Natural Science Foundation (7212084 for ZW).Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: All patients have informed consent and this study was approved by the ethics committees of the National Cancer Center (NCC-22/250-3454, NCC-22/429-3631). Patients without follow-up information were removed from further evaluation.

A Single-Cell Characterised Signature Integrating Heterogeneity and Microenvironment of Lung Adenocarcinoma for Prognostic Stratification

A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma.

A&nbsp;Novel Prognostic and Immunotherapeutic Predictive Model Based On&nbsp;cell-Originated Characterization of Tumor Microenvironment in Lung Adenocarcinoma

Integration of Multiple Key Molecules in Lung Adenocarcinoma Identifies Prognostic and Immunotherapeutic Relevant Gene Signatures.

Integrative analysis of single-cell and bulk RNA-sequencing data revealed T cell marker genes based molecular sub-types and a prognostic signature in lung adenocarcinoma

A Novel Prognostic Signature Revealed the Interaction of Immune Cells in Tumor Microenvironment Based on Single-Cell RNA Sequencing for Lung Adenocarcinoma.

Identification of Immune-Related Gene Signature Predicting Survival in the Tumor Microenvironment of Lung Adenocarcinoma.

Machine learning-based integration of CD8 T cell-related gene signatures for comprehensive prognostic assessment in lung adenocarcinoma

A novel gene expression signature-based on B-cell proportion to predict prognosis of patients with lung adenocarcinoma

Exploration of the prognostic signature reflecting tumor microenvironment of lung adenocarcinoma based on immunologically relevant genes

Identification of prognostic candidate signatures by systematically revealing transcriptome characteristics in lung adenocarcinoma with differing tumor microenvironment immune phenotypes

A Prognostic Nomogram Combining Immune-Related Gene Signature and Clinical Factors Predicts Survival in Patients with Lung Adenocarcinoma

Immune and non-immune cell subtypes identify novel targets for prognostic and therapeutic strategy: A study based on intratumoral heterogenicity analysis of multicenter scRNA-seq datasets in lung adenocarcinoma

Identification of an immune prognostic 11-gene signature for lung adenocarcinoma

Integrated Analysis of Single-Cell and Bulk RNA Sequencing Reveals a Malignancy-Related Signature in Lung Adenocarcinoma.

Development and Validation of a Robust Immune-Related Prognostic Signature in Early-Stage Lung Adenocarcinoma

Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma

A Prognostic Signature Model for Unveiling Tumor Progression in Lung Adenocarcinoma

Identification of a Six-Gene SLC Family Signature With Prognostic Value in Patients With Lung Adenocarcinoma

Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma

Identification of a Novel Tumor Microenvironment–Associated Eight-Gene Signature for Prognosis Prediction in Lung Adenocarcinoma